{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:39:53Z","timestamp":1762375193045},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.semradonc.2007.02.004","type":"journal-article","created":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T11:12:58Z","timestamp":1182942778000},"page":"184-189","source":"Crossref","is-referenced-by-count":29,"title":["Nodular Lymphocyte-Predominant Hodgkin Lymphoma"],"prefix":"10.1016","volume":"17","author":[{"given":"Henry K.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2007.02.004_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJM194407132310201","article-title":"Hodgkin\u2019s disease","volume":"231","author":"Jackson","year":"1944","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2007.02.004_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/path.1700800120","article-title":"The \u201cbenign\u201d form of Hodgkin\u2019s disease (Hodgkin\u2019s paragranuloma)","volume":"80","author":"Wright","year":"1960","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood.V11.3.211.211","article-title":"Mortality in relation to histologic type in Hodgkin\u2019s disease","volume":"11","author":"Smetana","year":"1956","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2007.02.004_bib4","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/1097-0142(196412)17:12<1595::AID-CNCR2820171212>3.0.CO;2-3","article-title":"Histological classification and survival in Hodgkin\u2019s disease: A study of 251 cases with special reference to nodular sclerosing Hodgkin\u2019s disease","volume":"17","author":"Hanson","year":"1964","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2007.02.004_bib5","first-page":"1063","article-title":"The pathology and nomenclature of Hodgkin\u2019s disease","volume":"26","author":"Lukes","year":"1966","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2007.02.004_bib6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2007.02.004_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib8","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/1097-0142(19830615)51:12<2293::AID-CNCR2820511221>3.0.CO;2-X","article-title":"Hodgkin\u2019s disease, lymphocytic predominance nodular","volume":"51","author":"Miettinen","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2007.02.004_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM198801283180404","article-title":"Nodular and diffuse types of lymphocyte predominance Hodgkin\u2019s disease","volume":"318","author":"Regula","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2007.02.004_bib10","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0","article-title":"Patterns of presentation of Hodgkin disease","volume":"71","author":"Mauch","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2007.02.004_bib11","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1200\/JCO.1989.7.9.1303","article-title":"A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin\u2019s disease","volume":"7","author":"Borg-Grech","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib12","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.1997.15.9.3060","article-title":"Clinical presentation and outcome in lymphocyte-predominant Hodgkin\u2019s disease","volume":"15","author":"Bodis","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.1989.7.1.81","article-title":"Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin\u2019s disease","volume":"7","author":"Leibenhaut","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0360-3016(98)00389-7","article-title":"Hodgkin\u2019s disease with lymphocyte predominance: Long-term results based on current histopathologic criteria","volume":"43","author":"Ha","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2007.02.004_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hon.782","article-title":"Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake","volume":"24","author":"Hutchings","year":"2006","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00390466","article-title":"Clinical features of nodular paragranuloma (Hodgkin\u2019s disease, lymphocyte predominance type, nodular)","volume":"108","author":"Hansmann","year":"1984","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2007.02.004_bib18","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogova","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib19","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.semradonc.2007.02.004_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: issues in delineating the radiation field in Hodgkin\u2019s disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2007.02.004_bib22","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2007.02.004_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","article-title":"A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment","volume":"51","author":"Girinsky","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2007.02.004_bib24","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0360-3016(02)03050-X","article-title":"Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia","volume":"54","author":"Johannsson","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2007.02.004_bib25","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","article-title":"High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas","volume":"21","author":"Haas","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib26","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ejca.2005.04.033","article-title":"Effective palliation by low dose local radiotherapy for recurrent and\/or chemotherapy refractory non-follicular lymphoma patients","volume":"41","author":"Haas","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2007.02.004_bib27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a059244","article-title":"Nodular type of lymphocyte predominant Hodgkin\u2019s disease","volume":"6","author":"Pappa","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2007.02.004_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0360-3016(94)E0136-8","article-title":"Lymphocyte predominant Hodgkin\u2019s disease: A clinicopathologic comparative study of histologic and immunophenotypic subtypes","volume":"31","author":"Crennan","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2007.02.004_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199709051786","article-title":"Nodular lymphocyte predominance Hodgkin\u2019s disease: Long-term observation reveals a continuous pattern of recurrence","volume":"26","author":"Orlandi","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semradonc.2007.02.004_bib30","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2007.02.004_bib31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","article-title":"Radiotherapy alone for lymphocyte-predominant Hodgkin\u2019s disease","volume":"8","author":"Schlembach","year":"2002","journal-title":"Cancer J"},{"key":"10.1016\/j.semradonc.2007.02.004_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/1097-0142(19870101)59:1<99::AID-CNCR2820590122>3.0.CO;2-J","article-title":"Lymphocyte predominance Hodgkin\u2019s disease","volume":"59","author":"Trudel","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2007.02.004_bib33","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.1990.8.12.1959","article-title":"Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin\u2019s disease","volume":"8","author":"Tefferi","year":"1990","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342960700015X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342960700015X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T18:37:26Z","timestamp":1587667046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105342960700015X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S105342960700015X"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2007.02.004","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}